DarunavirIn the Treatment of HIV-1 Infection

被引：0
作者：
Caroline Fenton
Caroline M. Perry
机构：
[1] Wolters Kluwer Health ¦ Adis,
[2] Wolters Kluwer Health,undefined
来源：
Drugs | 2007年 / 67卷
关键词：
Ritonavir; Virological Response; Atazanavir; Amprenavir; Darunavir;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
▲ Darunavir (TMC114) is a nonpeptidic peptidomimetic HIV protease inhibitor (PI), with a high binding affinity and a close fit within the substrate envelope.▲ Darunavir shows potent in vitro activity against a broad range of clinical isolates of HIV type 1 (HIV-1), including those with decreased susceptibility to most available PIs.▲ The bioavailability of oral darunavir is increased when it is coadministered with ritonavir. Thus, darunavir must be administered in combination with low-dose (100mg) ritonavir.▲ In the POWER 1 and POWER 2 trials, two 144-week randomised phase IIb trials, a reduction in plasma HIV-1 RNA levels of ≥1 log 10 copies/mL (primary endpoint) occurred in 77% and 62% of treatment-experienced recipients of darunavir plus ritonavir (darunavir/ritonavir) 600mg/100mg twice daily (in combination with an optimised background regimen) [vs 25% and 14% of control PI (CPI) recipients; p < 0.001] at week 24. Results are from primary analyses (n = 301 and 201).▲ In a pooled subgroup analysis of data from the POWER 1 and 2 trials, reductions in HIV-1 RNA levels of ≥1 log 10 copies/mL were achieved in 61% of patients treated with darunavir/ritonavir 600mg/ 100mg twice daily versus 15% of CPI recipients (p < 0.0001) at week 48.▲ Darunavir/ritonavir 600mg/100mg was generally well tolerated in the POWER 1 and 2 trials, with a tolerability profile similar to that of comparator CPIs.
引用
收藏
页码：2791 / 2801
页数：10
相关论文
共 50 条
[1]  
De Meyer S(2005)TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates Antimicrob Agents Chemother 49 2314-21
[2]  
Azijn H(2004)Meeting challenges: overcoming limitations. Advances of the protease inhibitor class: proceedings of an Expert Roundtable J Acquir Immune Defic Syndr 35 S1-2
[3]  
Surleraux D(2004)Pharmacokinetic considerations for combining 2 protease inhibitors AIDS Read 14 110-6
[4]  
Volberding PA(2004)Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor J Virol 78 12012-21
[5]  
Boffito M(2003)Novel bis-tetrahydrofurany-lurethane-containing nonpeptide protease inhibitor (PI) IUC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro Antimicrob Agents Chemother 47 3123-9
[6]  
Moyle GJ(2004)High resolution crystal structures of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) active against multi-drug-resistant clinical strains J Mol Biol 338 341-52
[7]  
King NM(2004)The influence of protease inhibitor resistance profiles on selection of HIV therapy in treatment-naive patients Antiviral Ther 9 301-14
[8]  
Prabu-Jeyabalan M(2003)Evolving therapeutic paradigms for HIV and HCV Curr Opin Biotechnol 14 634-40
[9]  
Nalivaika EA(2007)Safety and efficacy of darunavir (TMC114) With low-dose ritonavir in treatment-experienced Patients: 24-week results of POWER 3 J Acquir Immune Defic Syndr 46 24-31
[10]  
Koh Y(2005)TMC114/ritonavir substitution for protease inhibitor(s) in a non-suppressive antiretroviral regimen: a 14-day proof-of-principle trial AIDS 19 943-7
12345